Dhansa Labs Limited (DHANSA)
SME CapPharma stocks · SME cap · NSE
Dhansa Labs Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Dhansa Labs Limited (DHANSA) share analysis
Dhansa Labs Limited is a sme-cap NSE-listed company in Formulations. Its latest recorded share price is ₹35.75. IndiaPulse assigns it a U-Score of 18/100 and classifies its valuation as overvalued.
Current reported fundamentals include P/E of 17.5, P/B of 0.9, ROE of 5.6%, and debt/equity of 0.40. Review these figures alongside the company's growth, cash-flow, balance-sheet and peer evidence below.
For the quarter ended 30 Jun 2026, the result was classified as average with a score of 30/100. See the quarterly result breakdown.
- Market cap
- Rs 96 Cr
- P/E
- 17.5
- ROE
- 5.6%
- Debt/equity
- 0.40
- U-Score
- 18/100
- Latest result
- Average 30/100
Compare with Aristo Bio-Tech and Lifescience Ltd. (ARISTO), Onyx Biotec Ltd. (ONYX) and Sotac Pharmaceuticals Ltd. (SOTAC) or open the complete peer comparison.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust needs verification, price trend is neutral, and recent execution is weak.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Average · 30/100YoY data unavailable — classification deferred
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹30.6 Cr | NDF | -24.6% |
| EBITDA | ₹2.7 Cr | NDF | +8.6% |
| Operating margin | 8.7% | NDF | +265 bps |
| PAT | ₹0.7 Cr | NDF | -63.5% |
| PAT margin | 2.4% | NDF | -254 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Issuer presentation review pending
Dhansa Labs Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
Trend score and candlestick chart
59NeutralSMA20 +24.1% / mo · RSI overbought · MACD +
Technical chart
DHANSAdaily · 3Y · AUTO+71.9%Daily history is available from 2024-07-11; the requested 3Y window is partially covered.
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 84. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~19.4% over last month) — short-term momentum positive.
- RSI(14) at 84 — overbought zone; risk of mean reversion.
- MACD above signal, histogram expanding — bullish momentum building.
- 24% off 52W high · 121% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 18 · OVERVALUED · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 18 · OVERVALUED · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
OVERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Balance sheet contributes 9/15 to the score.
- Valuation contributes 15/30 to the score.
- Growth contributes 1/25 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Fair-value margin of safety is negative at -118.9%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -3 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Mixed Trust: Claim history is still being built. It ranks around the 25th percentile of the scored universe and 17th percentile within Pharma. Main check: cash conversion is weak at 40/100.
Mixed Trust Lite: Promoter holding is 65.9%. Key concern: Operating cash flow is negative at ₹-34 Cr.
Usable, but needs evidence. Treat guidance with a margin of safety.
overall median 67 · Pharma: 17th pctile, median 70 · SME: 27th pctile, median 64
0 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Mixed Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 65.9%.
- ▸Promoter pledge is zero.
Trust risks
- ▸Operating cash flow is negative at ₹-34 Cr.
- ▸Promoter holding fell 4.2%.
- ▸ROCE trend is -6.7%.
- ▸Fewer than 2 quarterly result rows available.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 17.50
- P/B
- 0.90
- EV/EBITDA
- 10.48
- Market Cap
- 96.20Cr
Profitability
- ROE
- 5.56%
- ROCE
- —
- ROA
- 3.97%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- —
- EPS 5Y
- —
- Revenue 3Y
- —
- EPS 3Y
- —
Balance Sheet
- Debt/Equity
- 0.40
- Interest Coverage
- 3.67×
- Altman Z
- 3.21
- Book Value
- 39.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- -4.00 Cr
- EPS TTM
- 2.21
Shareholding
- Promoter Hold
- 65.05%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 64%
Financial History
Updated 11/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.